Medication info
Sitafol MXR sustained-release tablet 50/500 mg

Sitafol MXR sustained-release tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
Bright blue oval-shaped sustained-release film-coated tablet with a convex surface on both sides
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202202000 · Approved 2022.05.12 · Insurance code 622804860

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate blood glucose control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate blood glucose control, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start with their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate blood glucose control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It works by combining sitagliptin and metformin to assist with dietary and exercise therapy, effectively improving blood sugar levels.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the drug was incompletely dissolved and excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the drug. If a patient repeatedly reports finding this drug in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Take 1 tablet of this drug 100/1000 mg extended-release tablets once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate blood glucose control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate blood glucose control, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient’s current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start with their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily as their current metformin dose may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate blood glucose control with concomitant metformin and sulfonylurea therapy, metformin and insulin therapy, or metformin and thiazolidinedione therapy: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin, and is primarily used for the treatment of type 2 diabetes. Severe allergic reactions may occur during the use of this medication, so if symptoms such as rash, hives, difficulty breathing, swelling of the face or neck occur, discontinue use immediately and consult a physician. Acute pancreatitis, a severe inflammation of the pancreas, can occur, so if symptoms such as abdominal pain, vomiting, or nausea arise, inform medical personnel immediately. Due to the metformin component, rare but fatal metabolic complications such as lactic acidosis may occur; if symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, or altered consciousness occur, discontinue use immediately and seek medical attention. Patients with moderate to severe renal impairment or with acute conditions that may affect kidney function like severe infection, dehydration, heart failure, acute myocardial infarction, or sepsis should not use this medication. In addition, this medication should be temporarily discontinued before and after examinations using iodine-based contrast agents, and should only be resumed once kidney function is confirmed to be normal. It is safest for women who are pregnant or may become pregnant and for nursing mothers to avoid using this medication. During the use of this medication, there is a heightened risk of hypoglycemia if there are irregular meals, excessive exercise, or if used in conjunction with other diabetic medications. Symptoms of hypoglycemia include dizziness, cold sweats, and severe fatigue; if these symptoms occur, consume sugar immediately or consult medical personnel. Regular kidney function tests, blood tests, and vitamin B12 level checks should be performed, and any unusual symptoms should be reported to medical personnel immediately. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is recommended to avoid alcohol while taking this medication. If surgery is planned, this medication should be discontinued 48 hours prior to the procedure, and should only be resumed after confirming that kidney function is normal post-surgery. Patients taking this medication should fully understand the effects and side effects of the drug, as well as the importance of lifestyle changes, and should consult with medical personnel regarding their treatment.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air, and should be kept at room temperature between 1 to 30 degrees Celsius. Proper storage ensures the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Bright blue oval-shaped sustained-release film-coated tablet with a convex surface on both sides

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.